Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Skin cancer management-updates on Merkel cell carcinoma.

Literature DB >> 30105232

Skin cancer management-updates on Merkel cell carcinoma.

Abstract

There are many different types of skin tumors in the World Health Organization (WHO) classification. The natural course and treatment varies according to the histological type. This review summarizes clinical experience for treatment decision. Contemporary radiotherapy and systemic therapy are improving. Landmark studies for basal cell and Merkel cell carcinomas (MCC) trigger further research and impetus for improving treatment outcome. Avelumab, nivolumab, pembrolizumab, ipilimumab appear to be promising for treatment of advanced MCCs and adjuvant trials are underway.

Entities: Chemical Disease

Keywords: Merkel cell carcinoma (MCC); PDL-1 inhibitor; immunotherapy; radiotherapy

Year: 2018 PMID： 30105232 PMCID： PMC6068322 DOI： 10.21037/atm.2018.06.13

Source DB: PubMed Journal: Ann Transl Med ISSN： 2305-5839

19 in total

Review 1. Research gaps in the management and prevention of cutaneous squamous cell carcinoma in organ transplant recipients.

Authors: M Blomberg; S Y He; C Harwood; S T Arron; S Demehri; A Green; M M Asgari
Journal: Br J Dermatol Date: 2017-10-30 Impact factor: 9.302

2. Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma.

Authors: Shalini V Mohan; Julia Chang; Shufeng Li; A Solomon Henry; Douglas J Wood; Anne Lynn S Chang
Journal: JAMA Dermatol Date: 2016-05-01 Impact factor: 10.282

3. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial.

Authors: Brigitte Dréno; Rainer Kunstfeld; Axel Hauschild; Scott Fosko; David Zloty; Bruno Labeille; Jean-Jacques Grob; Susana Puig; Frank Gilberg; Daniel Bergström; Damian R Page; Gary Rogers; Dirk Schadendorf
Journal: Lancet Oncol Date: 2017-02-08 Impact factor: 41.316

Review 4. Nicotinamide and the skin.

Authors: Andrew C Chen; Diona L Damian
Journal: Australas J Dermatol Date: 2014-03-17 Impact factor: 2.875

5. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.

Authors: Andrew C Chen; Andrew J Martin; Bonita Choy; Pablo Fernández-Peñas; Robyn A Dalziell; Catriona A McKenzie; Richard A Scolyer; Haryana M Dhillon; Janette L Vardy; Anne Kricker; Gayathri St George; Niranthari Chinniah; Gary M Halliday; Diona L Damian
Journal: N Engl J Med Date: 2015-10-22 Impact factor: 91.245

Review 6. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases.

Authors: P T Tai; E Yu; E Winquist; A Hammond; L Stitt; J Tonita; J Gilchrist
Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544

7. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

Authors: Howard L Kaufman; Jeffery Russell; Omid Hamid; Shailender Bhatia; Patrick Terheyden; Sandra P D'Angelo; Kent C Shih; Céleste Lebbé; Gerald P Linette; Michele Milella; Isaac Brownell; Karl D Lewis; Jochen H Lorch; Kevin Chin; Lisa Mahnke; Anja von Heydebreck; Jean-Marie Cuillerot; Paul Nghiem
Journal: Lancet Oncol Date: 2016-09-01 Impact factor: 41.316

Skin cancer management-updates on Merkel cell carcinoma.

Review 1. Research gaps in the management and prevention of cutaneous squamous cell carcinoma in organ transplant recipients.

2. Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma.

3. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial.

Review 4. Nicotinamide and the skin.

5. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.

Review 6. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases.

7. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

8. Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma.

9. A practical update of surgical management of merkel cell carcinoma of the skin.

10. 1-methylnicotinamide and its structural analog 1,4-dimethylpyridine for the prevention of cancer metastasis.

1. Outcome of early stage Merkel carcinoma treated by exclusive radiation: a study of 53 patients.